A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

Summary

This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c in adult patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control with diet and exercise and stable metformin treatment.

Timeline

Start

2022-03-29

Primary completion

2023-05-30

Completion

2023-05-30

Outcome

Outcome not reported

Stopped (Business): “Terminated due to financial constraint.”

Drugs

Indications